Charles A. Stanley. M.D. Dr. Stanley is the founder of the Congenital Hyperinsulinism Center at the Children’s Hospital of Philadelphia and a professor emeritus of pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Stanley is a world- renowned expert on disorders of insulin regulation in children. He has helped define the various types of hyperinsulinism (HI) and pioneered best practices for diagnosis and treatment of congenital HI. Dr. Stanley has published numerous articles in journals such as The New England Journal of Medicine, Journal of Pediatrics, Diabetes, Journal of Clinical Endocrinology and Metabolism, and The Journal of Biological Chemistry. In conjunction with his published work, Dr. Stanley has also lectured extensively around the world about the causes and treatment of congenital hyperinsulinism and hypoglycemia (low blood sugar) in neonates and young children. Dr. Stanley earned his bachelor’s degree in biochemical sciences from Harvard University, Cambridge, MA, and his medical degree from the University of Virginia School of Medicine, Charlottesville, VA. He completed his residency in pediatrics and a fellowship in metabolic diseases, both at Children’s Hospital of Philadelphia, Philadelphia, PA.
Marvin Caruthers, Ph.D. Marvin H. Caruthers, Ph.D., is a Distinguished Professor of Chemistry and Biochemistry at the University of Colorado and a pioneer in the biotechnology field. One of the co-founders of Amgen and Applied Biosystems, Dr. Caruthers’ groundbreaking scientific research in nucleic acid chemistry led to the development of DNA synthesizing techniques that remain the industry standard today. Dr. Caruthers is also a founding investor in miRagen Therapeutics and member of the Board. Dr. Caruthers holds a B.S. in Chemistry from Iowa State University and a Ph.D. in Biochemistry from Northwestern University. A Guggenheim Fellow, he is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Dr. Caruthers was awarded the National Medal of Science for 2006, the nation’s highest distinction honoring scientific achievement.
Robert S. Hodges, Ph.D. Dr. Hodges is a Professor of Biochemistry and Molecular Genetics and holder of the John Stewart Endowed Chair in Peptide Chemistry at the University of Colorado, School of Medicine. At the University of Alberta he became a founding member of the Medical Research Council of Canada Group on Protein Structure and Function, Director of the Alberta Peptide Institute and Network Leader of the Protein Engineering Network of Centres of Excellence, a national network. Dr. Hodges has received many awards among which are the distinguished MRC Scientist Award (considered to be the most prestigious of such awards in Canada), the Boehringer-Mannheim Award from the Canadian Society of Biochemistry and Molecular Biology (in recognition of a record of outstanding achievement in research in the field of Biochemistry), the Vincent du Vignead Award from the American Peptide Society (for outstanding achievements in peptide research) and in 2009 Inventor of the Year award at the University of Colorado Denver. In addition, he has been President and CEO, member of Boards of Directors, and consultant to many biotech companies. His research interests are diverse with over 500 publications and 48 patents/patent applications to his credit.
John P. Mayer, Ph.D. Dr. Mayer is a recognized leader in peptide discovery and has recently joined the University of Indiana as a Senior Research Scientist. Prior to this role, Dr. Mayer served as a Senior Research Advisor and Group Leader of Peptide Chemistry at Eli Lilly and Co. He has also served in a similar capacity as Peptide Chemistry Group Leader with Amgen, Inc. Dr. Mayer has a B.S. in Biochemistry from Northwestern University and a MS and Ph.D. in Medicinal Chemistry from Purdue University. He currently sits on numerous advisory and editorial boards and is the author or co-author of over 50 publications and 15 applied or issued patents.
Gilad S. Gordon, M.D., M.B.A. Dr. Gilad S. Gordon serves as Clinical Associate Professor of Medicine at the University of Colorado Health Sciences Center and is a Principal of the ORRA Medical Consulting Group, providing expertise in the development and implementation of clinical trial programs in the biotechnology and pharmaceutical industries. Dr. Gordon brings over 20 years of Industrial and Academic experience, including tenures at Eli Lilly Company, Synergen, Ribozyme Pharmaceuticals, and FeRx. Dr. Gordon is a recognized authority in the areas of new drug research and development, clinical trial design and execution, and regulatory compliance in the healthcare industry, focusing on the areas of oncology, hepatology, and immunology. He has received awards of recognition from Harvard Medical School, the American College of Physicians, and the American College of Chest Physicians. Dr. Gordon received his A.B. in Biochemistry from Harvard University, his M.D. from Harvard University/Massachusetts Institute of Technology, and his M.B.A from the University of Washington. In addition to serving on the board of directors of the Caring for Colorado Foundation, and the University of Colorado Institutional Review Board, Dr. Gordon is an active attending physician at the Denver Veteran’s Administration Hospital.